<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02813642</url>
  </required_header>
  <id_info>
    <org_study_id>UF8851</org_study_id>
    <nct_id>NCT02813642</nct_id>
  </id_info>
  <brief_title>Evaluation of Cardiovascular Risk Factors in Incident Dialysis Patients</brief_title>
  <official_title>Evaluation of Non Traditional Cardiovascular Risk Factors in Chronic Kidney Disease Patients Starting Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the relationships between bone mineral markers levels at dialysis start and
      vascular calcification progression during a 2 year follow up
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of vascular calcifications during a 2 year follow up according to plasma osteoprotegerin level at inclusion</measure>
    <time_frame>2 years after inclusion</time_frame>
    <description>osteoprotegerin will be measured in picomol/L; vascular calcifications will be measured at inclusion and after the 2 year follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression of vascular calcifications during a 2 year follow up according to plasma fibroblast growth factor 23 level at inclusion</measure>
    <time_frame>2 years after inclusion</time_frame>
    <description>fibroblast growth factor 23 will be measured in RU/milliliter; vascular calcifications will be measured at inclusion and after the 2 year follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of cardiovascular events during a 2 year follow up</measure>
    <time_frame>2 years after inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Cardiovascular risk evaluation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measurement of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 2 year follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasma osteoprotegerin level</intervention_name>
    <description>dosage of plasma osteoprotegerin</description>
    <arm_group_label>Cardiovascular risk evaluation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasma fibroblast growth factor 23 level</intervention_name>
    <description>dosage of plasma fibroblast growth factor 23</description>
    <arm_group_label>Cardiovascular risk evaluation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vascular calcification score</intervention_name>
    <description>measurement of vascular calcification score by X-ray of the lateral abdominal aorta</description>
    <arm_group_label>Cardiovascular risk evaluation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who has signed the written consent form

          -  Patient with chronic renal failure starting dialysis therapy

        Exclusion Criteria:

          -  Pregnancy

          -  Patient with chronic renal failure not yet on dialysis therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul Cristol, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Lapeyronie, Department of Biochemistry and Hormonology, Montpellier, FRANCE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Paul Cristol, Prof</last_name>
    <phone>+33(0)4 67 33 83 15</phone>
    <email>jp-cristol@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion Morena, PhD</last_name>
    <phone>+33(0)4 11 75 98 93</phone>
    <email>m-morenacarrere@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hémodialyse du Lez</name>
      <address>
        <city>Castelnau Le Lez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien Deleuze, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Sébastien Deleuze, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AIDER</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lotfi Chalabi, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Lotfi Chalabi, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier, Nephrology department</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène Leray-Moragues, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Hélène Leray-Moragues, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leila Chenine, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Nimes, Nephrology department</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Reboul, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Pascal Reboul, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Perpignan, Nephrology department</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Vela, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Carlos Vela, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2016</study_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic kidney disease starting dialysis</keyword>
  <keyword>cardiovascular risk</keyword>
  <keyword>bone mineral metabolism markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

